Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.
Clin Nucl Med
; 41(1): 53-4, 2016 Jan.
Article
en En
| MEDLINE
| ID: mdl-26562579
ABSTRACT
A 70-year-old woman presented with frequent episodes of hypoglycemia. Imaging revealed a 6-cm pancreatic mass with several liver lesions. The pancreatic mass was resected and confirmed to be a well-differentiated insulinoma. Surgery improved but did not resolve her hypoglycemic episodes, and she was referred for peptide receptor radionuclide therapy with 177Lu-DOTATATE to treat her residual disease. A modified protocol with a continuous IV dextrose infusion was used, and the treatments were well tolerated. After 4 induction and 2 maintenance treatments, her hypoglycemic symptoms resolved completely and her disease stabilized. She has been progression free for 24 months.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Compuestos Organometálicos
/
Neoplasias Pancreáticas
/
Octreótido
/
Receptores de Péptidos
/
Tumores Neuroendocrinos
/
Insulinoma
Tipo de estudio:
Guideline
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Clin Nucl Med
Año:
2016
Tipo del documento:
Article
País de afiliación:
Canadá